Enrollment is pending for our Phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
For Our Upcoming Clinical Trial in Australia:
NCT06442462 Status: not yet recruiting; please continue to check the status at ClinicalTrials.gov